VANCOUVER, British Columbia, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox's President & CEO, will present a corporate overview at two upcoming investor conferences.
17th Annual BIO CEO & Investor Conference
Monday, February 9, 2015, at 9:00 AM Eastern Time - Waldorf Astoria Hotel, New York, NY
A live audio webcast and archive of the event will be available at: http://www.veracast.com/webcasts/bio/ceoinvestor2015/22104478202.cfm
2015 Leerink Global Healthcare Conference
Wednesday, February 11, 2015, at 3:55 PM Eastern Time - Waldorf Astoria Hotel, New York, NY
A live audio webcast and archive of the event will be available at: http://leerink.metameetings.com/confbook/healthcare15/directlink?ticker=AQXP
The corporate overview being presented at both conferences will be available at: http://aqxpharma.com/content/about-us
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has successfully completed multiple preclinical studies and clinical trials with AQX-1125 and is advancing through Phase 2 development. The company has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
Communications Contact Info:
Senior Account Executive
MacDougall Biomedical Communications
Source:Aquinox Pharmaceuticals, Inc.